|Mr. Thian Chew||Executive Chairman & CEO||545.77k||N/A||N/A|
|Ms. Melanie Jaye Leydin B.Bus, C.A.||Chief Financial Officer||N/A||N/A||1973|
|Dr. Dean Naylor||Head of Intellectual Property Development||N/A||N/A||N/A|
|Ms. Claire Newstead-Sinclair BBus, C.A., CA||Company Secretary||N/A||N/A||N/A|
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, anogenital, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Invion Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.